Early PET/CT Scan Predicts Which HER2-Positive Breast Cancers Will Vanish Before Surgery
A prospective study finds that 68Ga-HER2 PET/CT scans after just two cycles of neoadjuvant therapy can predict which HER2-positive breast ...
A prospective study finds that 68Ga-HER2 PET/CT scans after just two cycles of neoadjuvant therapy can predict which HER2-positive breast ...
A retrospective study of 138 premenopausal women with hormone receptor-positive, HER2-positive breast cancer found no independent survival benefit from adding ...
A phase Ib/II trial testing famitinib added to dalpiciclib and fulvestrant in HR-positive, HER2-negative advanced breast cancer met early response ...
A multicenter phase II trial found that a pyrotinib-based neoadjuvant regimen achieved pathological response rates comparable to the standard trastuzumab-pertuzumab ...
Chemists have designed nine 1,3,4-oxadiazole derivatives that inhibit breast cancer cells in vitro, with the lead compound R3 showing an ...
A new computational study shows that the plant flavonoid kaempferol and the chemotherapy drug docetaxel both bind strongly to the ...
A decade after professional guidelines discouraged contralateral prophylactic mastectomy for average-risk breast cancer patients, a study of 6,203 women at ...
Breast cancer patients receiving injectable gonadotropin-releasing hormone agonist therapy may be able to shift a significant part of their treatment ...
In a landmark development that could redefine the standard of care in breast cancer treatment, the largest randomized controlled trial ...
Recent landmark findings from the NRG-NSABP B-51/RTOG 1304 clinical trial have delivered a paradigm-shifting insight into the management of breast ...
© 2025 Scienmag - Science Magazine
© 2025 Scienmag - Science Magazine